Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Accretion Pharmaceuticals Ltd. Share Price
Day's Range
Day's Range
Low
₹156.15
High
₹159.00
Price Summary
| Previous Close | ₹159.00 |
|---|---|
| Day's Range | ₹156.15 - ₹159.00 |
| Open | ₹156.15 |
| 52 Week Range | ₹53.80 - ₹171.15 |
| Volume | 6,000 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 9.54 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 18.06 |
| TTM EPS (₹) | 8.70 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 3.19 |
| PAT Margin (%) | 11.84 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 46.33 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | N/A | 573.76 |
| Expenses | N/A | N/A |
| PBT | N/A | 97.64 |
| Operating profit | N/A | 0.0 |
| Net profit | N/A | 67.94 |
About Accretion Pharmaceuticals Ltd.
| Founded | 2023 |
|---|---|
| Managing Director | Vivek Ashok Kumar Patel |
| NSE Symbol | ACCPL |
Latest News
Gujarat Themis Biosyn informs about disclosure
Gujarat Inject Kerala informs about outcome of board meeting
Pursuant to Regulations 30, 33 and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Gujarat Inject Kerala has informed that the Board of Directors of the Company at its meeting held today Wednesday, 15th July, 2026 has discussed, approved, and taken on record the following matter: 1. Approved Un-Audited Financial Results of the Company for the First Quarter ended on 30th June, 2026; and 2. took on record ‘Limited Review Report’ thereon issued by S Mandawat & Co., Statutory Auditors of the Company. A copy of the approved Un-Audited Financial Results along with Limited Review Report are enclosed. The meeting commenced at 09:00 am and concluded at 09:45 am at the Registered Office of the Company.
The above information is a part of company’s filings submitted to BSE.
Sun Pharmaceutical Industries informs about press release
Sun Pharmaceutical Industries has informed that it enclosed a copy of the press release titled ‘Sun Pharma receives approval to manufacture and market generic semaglutide in South Africa,’ which shall be released after this intimation.
The above information is a part of company’s filings submitted to BSE.
Zenith Healthcare informs about amalgamation
Aster DM Healthcare informs about disclosures
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Accretion Pharmaceuticals Ltd. is ₹159.00 as of 2026-07-15.
The market capitalisation of Accretion Pharmaceuticals Ltd. is ₹174.63 as of 2026-07-14.
The 1-year return of Accretion Pharmaceuticals Ltd. is 92.10% as of 2026-07-15.
The P/E ratio of Accretion Pharmaceuticals Ltd. is 0.00 as of 2026-07-15.
The 52-week high and low of Accretion Pharmaceuticals Ltd. are ₹171.15 and ₹53.80, respectively, as of 2026-07-15.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
